Studies of the effects of antiretroviral drugs on lipid metabolism are limited by the availability of suitable models. We have thus developed an animal model utilising Göttingen mini-pigs. The normal lipid metabolism of mini-pigs closely reflects that of humans and they are expected to have similar reactions to antiretroviral drugs.
Methods
The pigs were treated orally with high doses of the protease inhibitors ritonavir and saquinavir for 4 weeks. The model allows repeated concomitant biopsies from liver, muscle, adipose tissue and plasma samples.
Results
The study showed a general decrease in poly-unsaturated fatty acids; changes in both saturated and monounsaturated fatty acids were also apparent after antiretroviral treatment. The changes were observed after 4 weeks of treatment. At 4 weeks post-treatment, the levels of all fatty acids were lower compared with pre-treatment levels, suggesting a prolonged effect of the antiretroviral drug treatment lasting beyond the 4 week post-treatment observation period.
Conclusions
The Göttingen mini-pig model is a promising animal model for rapid screening of the metabolic effects induced by antiretroviral drugs.
References
1.
CarrA., EmeryS., LawM.An objective case definition of lipodystrophy in HIV-infected adults: a case-control study.Lancet2003; 361: 726–735.
2.
DAD Study Group, Friis-MøllerN., ReissP.Class of antiretroviral drugs and the risk of myocardial infarction.N Engl J Med2007; 356: 1723–1735.
3.
D:A:D Study Group, SabinC.A., WormS.W.Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.Lancet2008; 371: 1417–1426.
4.
ParkerR.A., FlintO.P., MulveyR.Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors.Mol Pharmacol2005; 67: 1909–1919.
5.
SquillaceN., ZonaS., StentarelliC.Detectable HIV viral load is associated with metabolic syndrome.J Acquir Immune Defic Syndr2009; 52: 459–464.
6.
CarrA., RitzhauptA., ZhangW.Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.AIDS2008; 22: 2313–2321.
7.
TebasP.Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options.J Acquir Immune Defic Syndr2008; 49 Suppl 2: S86–S92.
8.
FlintO.P., NoorM.A., HruzP.W.The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications.Toxicol Pathol2009; 37: 65–77.
9.
ReedsD.N., MittendorferB., PattersonB.W., PowderlyW.G., YarasheskiK.E., KleinS.Alterations in lipid kinetics in men with HIV-dyslipidemia.Am J Physiol Endocrinol Metab2003; 285: E490–E497.
10.
GhibelliL., MengoniF., LichtnerM.Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain.Biochem Pharmacol2003; 66: 1505–1512.
11.
CarrA., SamarasK., ChisholmD.J., CooperD.A.Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.Lancet1998; 351: 1881–1883.
12.
WalkerU.A., BickelM., Lütke VolksbeckS.I.Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients.J Acquir Immune Defic Syndr2002; 29: 117–121.
13.
RanadeK., GeeseW.J., NoorM.Genetic analysis implicates resistin in HIV lipodystrophy.AIDS2008; 22: 1561–1568.
14.
AdeyemiO., RezaiK., BahkM., BadriS., Thomas-GossainN.Metabolic syndrome in older HIV-infected patients: data from the CORE50 cohort.AIDS Patient Care STDS2008; 22: 941–945.
15.
MallonP. W.. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy.AIDS Rev2007; 9: 3–15.
16.
NtawubiziM., RaesK., BuysN., De SmetS.Relationships between indices for desaturase and elongase activity involved in the intramuscular long chain polyunsaturated fatty acid metabolism in pigs.Commun Agric Appl Biol Sci2007; 72: 29–33.
17.
HsuA., GrannemanG.R., WittG.Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects.Antimicrob Agents Chemother1997; 41: 898–905.
18.
JustesenU.S.Protease inhibitor plasma concentrations in HIV antiretroviral therapy.Dan Med Bull2008; 55: 165–184.
19.
JustesenU.S., FoxZ., PedersenC.Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.Basic Clin Pharmacol Toxicol2007; 101: 339–344.
20.
KotlerD.P.HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients.J Acquir Immune Defic Syndr2008; 49 Suppl 2: S79–S85.
21.
PurnellJ.Q., ZambonA., KnoppR.H.Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.AIDS2000; 14: 51–57.
22.
MartínezE., García-ViejoM.A., BlancoJ.L.Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy.Clin Infect Dis2000; 31: 1266–1273.
23.
BastardJ.P., CaronM., VidalH.Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance.Lancet2002; 359: 1026–1031.
24.
JonesS.P., QaziN., MoreleseJ.Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.J Acquir Immune Defic Syndr2005; 40: 565–572.
25.
LagathuC., KimM., MaachiM.HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo.Biochimie2005; 87: 65–71.
26.
MallewaJ.E., WilkinsE., VilarJ.HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options.J Antimicrob Chemother2008; 62: 648–660.
RanganathanS., KernP.A.The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocyte.J Endocrinol2002; 172: 155–162.
29.
NoorM.A., SeneviratneT., AweekaF.T.Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.AIDS2002; 16: 1–8.
QinY., DalenK.T., GustafssonJ.A., NebbH.I.Regulation of hepatic fatty acid elongase 5 by LXRalpha-SREBP-1c.Biochim Biophys Acta2009; 1791: 140–147.
32.
WangY., BotolinD., XuJ.Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity.J Lipid Res2006; 47: 2028–2041.
33.
RasheedS., YanJ.S., LauA., ChanA.S.HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study.PLoS ONE2008; 3: e3003.
34.
MurakamiK., SasakiS., TakahashiY.Lower estimates of delta-5 desaturase and elongase activity are related to adverse profiles for several metabolic risk factors in young Japanese women.Nutr Res2008; 28: 816–824.
35.
MatsuzakaT., ShimanoH., YahagiN.Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance.Nat Med2007; 13: 1193–1202.
36.
TanakaT., ShenJ., AbecasisG.R.Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study.PLoS Genet2009; 5: e1000338.
37.
HaraK., YamauchiT., KadowakiT.Adiponectin: an adipokine linking adipocytes and type 2 diabetes in humans.Curr Diab Rep2005; 5: 136–140.
38.
LindegaardB., KellerP., BruunsgaardH., GerstoftJ., PedersenB.K.Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients.Clin Exp Immunol2004; 135: 273–279.
39.
LiangJ.S., DistlerO., CooperD.A.HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia.Nat Med2001; 7: 1327–1331.
40.
KoutkiaP., CanavanB., BreuJ., GrinspoonS.Effects of growth hormone-releasing hormone on bone turnover in human immunodeficiency virus-infected men with fat accumulation.J Clin Endocrinol Metab2005; 90: 2154–2160.
41.
BrennanA.M., LeeJ.H., TsiodrasS.r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans.Eur J Endocrinol2009; 160: 173–176.
